CAR1922T2 T cells therapy(Tongji Hospital)

N/A

Report date: 2026/02/15 20:00:16

Base Information

Drug NameCAR1922T2 T cells therapy(Tongji Hospital)

Drug Alias NameNovel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 therapy(Tongji Hospital)CAR1922T2

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTongji Hospital

China Registration ClassN/A

Develop Information

Active CompaniesTongji Hospital

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A